 |
October 1957
Alumni Bulletin
Fall/Winter 1982
Yale Medicine |
|
October 1957
Alumni Bulletin
New Integrated Course in Basic Neurology
“The extensive growth of knowledge concerning the nervous system
resulting from work in the fields of anatomy, physiology, psychology,
biochemistry and pharmacology in recent years is causing many medical
schools to re-evaluate the organization of basic science courses related
to the nervous system. This problem has been under discussion at Yale
for several years, and this winter an integrated program in the teaching
of neuroanatomy and neurophysiology will begin with the initiation of
a first-year course, ‘Introduction to the Nervous System.’
“This course will be presented jointly by the Departments of Anatomy
and Physiology with the cooperation of the Sections of Neurology and Neurosurgery.
The program will consist of lectures, demonstrations, laboratory exercises,
conferences and correlation clinics covering the basic structure and function
of the nervous system. In addition to the presentation of fundamental
concepts of normal morphology and activity, the program will endeavor
to introduce the first-year medical students to the use of quantitative
analytical methods and the rudiments of experimental design through laboratory
experiments applied to the nervous system.”
Fall/Winter 1982
Yale Medicine
Yale Enters a Cooperative Research Agreement With Bristol-Myers for
Development of Anticancer Drugs
“Bristol-Myers Company and Yale University have entered into a $3
million cooperative research agreement to facilitate the production and
availability of new anticancer drugs.
“The agreement brings the investigative talents of Yale medical
scientists, who are recognized leaders in cancer chemotherapy research,
together with the research and developmental resources of Bristol-Myers
Company, a major producer and distributor worldwide of anticancer agents.
Through ongoing technical and scientific interaction, they will seek to
employ the unique resources and skills of university- and industry-based
approaches to development and production of new effective and safe drugs
for the diagnosis and treatment of neoplastic diseases. …
“Yale is one of very few research institutions in the world where
scientists involved in the development of a new anticancer drug work together
from the first experiments at the laboratory bench through to treating
patients in the clinic. They played a leading role in the development
of several important drugs, and in addition, they have been conducting
research to increase the effectiveness and reduce the toxic side effects
of a number of drugs which have been used with some success, by revising
the scheduling of their administration, and by utilizing them in combination.”
|
|
|
